Orphan Drug Is Headed Back to Its Parent

NPS Pharmaceuticals (NASDAQ: NPSP  ) is bringing its kids home. The biotech announced yesterday that it had reacquired the ex-North America rights to two drugs -- Revestive and Preotact -- that were licensed to Nycomed, which was subsequently acquired by Takeda Pharmaceutical.

Investors clearly liked the idea. Shares jumped 9.3% on the news. I'm not quite sure it's a good sign.

Preotact is approved in Europe for treating post-menopausal osteoporosis, but a majority of the value of the deal is for Revestive, which goes by Gattex in the states. Revestive was approved last year to treat an orphan disease called short bowel disease.

Takeda is letting go of the drugs for $50 million worth of NPS Pharmaceuticals stock up front. The biotech is also on the hook for another $30 million payment if the combined sales of the two drugs exceed $750 million in a calendar year.

That's pretty darn cheap. Back in 2007, Nycomed paid NPS $35 million up front just for the rights to Revestive. And the deal for the drug, which hadn't yet completed phase 3, included more than $150 million in additional milestone payments.

It could be that NPS is getting a great deal, but my guess is Takeda has looked at the potential market and realized it was too small to bother with. Presumably Takeda, with its larger presence outside North America, could market the drugs for cheaper than NPS will be able to do. Building out a commercial presence in Europe isn't going to be easy or cheap.

Regaining the rights to Revestive and Preotact makes NPS a more attractive takeover target. That might be the main driver for the increased valuation.

There's certainly precedence. Amylin Pharmaceuticals regained the rights to Byetta and Bydureon from Eli Lilly (NYSE: LLY  ) and was subsequently purchased by a joint venture of Bristol-Myers Squibb (NYSE: BMY  ) and AstraZeneca (NYSE: AZN  ) . It's unlikely that Bristol-AstraZeneca would have made the purchase if Eli Lilly were still involved. It was a win-win-hopefully win. Eli Lilly was able to pursue other diabetes drugs and still get milestones and royalty payments, Amylin's investors saw shares nearly triple in value. It helped Bristol and AstraZeneca build out their diabetes franchise, although it's still to be determined whether the duo overpaid for the diabetes specialist.

I wouldn't buy NPS on the hopes of a quick buyout, though. Any potential buyers will likely want to see how Gattex/Revestive performs on the market before they make a bid. NPS will have to prove the doubters wrong -- Takeda included -- before it'll get bought out.

Is Eli Lilly a buy or sell?
With two of its top three drugs poised to lose patent protection this year, is Eli Lilly a dividend stock headed nowhere fast? In a new premium report, The Motley Fool's senior pharmaceuticals analyst breaks down all of Lilly's moving parts, including an in-depth analysis of the company's must-know opportunities and reasons to buy and sell today. To find out more click here to claim your copy today.


Read/Post Comments (1) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On March 20, 2013, at 5:04 PM, faosto wrote:

    I'm not certain you understand the marketing for GATTEX. If you do, then I don't. It will be marketed to a well-defined group of docs and patients. There are less than 5000 patients worldwide. If all 5000 used GATTEX, it would be a billion dollar drug. $350-$500 mill is more like it. But it doesn't require a huge salesforce or infrastructure. These patients are known to specialists. And in the US, NPS already has a database of over 1500 patients.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2323513, ~/Articles/ArticleHandler.aspx, 11/1/2014 2:54:12 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement